Purpose and Brief Explanation of Study:
Cardiogenic embolism is a common sequela of heart muscle disease (cardiomyopathy in cats leading to debilitating clinical signs including severe pain, neurologic deficits, renal failure, congestive heart failure, and death. Feline thromboembolic disease is predisposed by left atrial enlargement and dysfunction, leading to blood stasis and thrombus formation.
This study will test the hypothesis that Pimobendan, a drug that enhances myocardial contractility and reduces cardiac workload, will increase left atrial transport function, accelerate intracardiac blood flow, and thus reduce blood stasis in cats with hypertrophic cardiomyopathy (HCM) and left atrial enlargement. If confirmed, Pimobendan may become as a novel treatment option in the prevention of thromboembolic disease in cats with cardiomyopathy.
Objective of the trial:
The goal of this study is to prove that Pimobendan improves atrial function and thus prevents stagnating blood flow, possibly preventing the development of thromboembolic disease, a common and often deadly consequence of hypertrophic cardiomyopathy.
What qualifies my cat for enrollment in this in this trial?
To participate in this clinical trial your cat must have:
- A diagnosis of hypertrophic cardiomyopathy (non-obstructive disease)
- Left atrial enlargement
What does enrolling my cat in this clinical trial involve?
Procedures (at 2 visits 4 to 7 days apart):
- Physical examination
- Non-invasive blood pressure measurement
- Blood draw for biochemical analysis of a renal panel and total thyroxin concentration
- Transthoracic echocardiography
- Sedation (intramuscular injection of a mild sedative)
- Thoracic radiography (only in cats with suspected congestive heart failure)
The costs covered by the study include the recheck examination fee, repeated echocardiogram free, repeated blood pressure free, repeated sedation administration free and there will be a $100 incentive for client-owned cats at the initial examination.
If you believe your pet may be eligible to enter this study, please click here to fill out a questionnaire.
Dr. Michelle Rohrbaugh email@example.com